FDA Fast-Tracks Psychedelic Drug Research Following Trump Executive Order
Federal agency announces major shift toward supporting psychedelic-based medicines for treatment-resistant depression, PTSD and substance use disorders.
Read the full reporting at CNBC Markets.
Originally reported by CNBC Markets.